OTX-2002 is under clinical development by Omega Therapeutics and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OTX-2002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OTX-2002 overview

OTX-2002 is under development for the treatment of hepatocellular carcinoma and solid tumors, colorectal cancer, soft tissue sarcoma, cervical cancer, pancreatic cancer. The drug candidate is an epigenomic controller that comprises of a DNA-binding domain and an epigenetic effector domain delivered as mRNA via lipid nanoparticles (LNPs) to modulate the gene expression. It is administered through intravenous route. It acts by targeting oncogene MYC and is being developed based on OMEGA epigenomic programming platform.

Omega Therapeutics overview

Omega Therapeutics is a biotechnology company that focuses on developing genomic medicines through epigenomic programming. The company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of OTX-2002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.